Comparative Pharmacology
Head-to-head clinical analysis: TOTACILLIN versus VEETIDS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOTACILLIN versus VEETIDS 250.
TOTACILLIN vs VEETIDS '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal: inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation. Active against gram-positive bacteria and some gram-negative bacteria.
VEETIDS '250' is an oral cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP-3, thereby disrupting peptidoglycan cross-linking and leading to cell lysis.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours.
250 mg orally every 8 hours for 7-10 days
None Documented
None Documented
Terminal elimination half-life: 1.0-1.5 hours in normal renal function. Extended to 2-6 hours in renal impairment; requires dose adjustment when CrCl <30 mL/min.
2-3 hours in adults with normal renal function; prolonged to 24-40 hours in anuria/end-stage renal disease, requiring dose adjustment.
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5% as unchanged drug and metabolites.
Primarily renal (≥90% as unchanged drug) via glomerular filtration and tubular secretion; minor biliary/fecal (<5%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic